Volume Alert - GILD 101.85 Gilead Sciences $GILD H
Post# of 162
Posted On: 11/19/2014 11:38:04 AM
Volume Alert - GILD 101.85 Gilead Sciences $GILD Hit a high today of 103.32 Closing the day 10:30 at 101.85 -1.86 -1.79% With a day low of 101.01 and a total volume of 3,875,514.
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Update: Gilead's Harvoni Receives Marketing Authorization In Europe
IAEResearch - at Seeking Alpha - 19 mins ago
GILD: 101.83 (-1.88)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 27 mins ago
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 28.78 (-0.01), AGN: 213.41 (+0.04), HD: 97.18 (+1.20), ACT: 268.15 (-1.45), GILD: 101.83 (-1.88), PFE: 30.35 (-0.24), COV: 97.88 (-0.21), ALXN: 192.83 (+0.46)
Knight Sells Priority Review Voucher to Gilead
Marketwire Canada - Wed Nov 19, 7:00AM CST
Knight Therapeutics Inc., (TSX:GUD) through one of its wholly owned subsidiaries ("Knight"
, today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV" . The PRV was granted to Knight in March of this year with the approval of Impavido(R) (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis. Upon closing of the transaction, Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV. Knight was advised in the transaction by global investment banking firm, Jefferies LLC.
GILD: 101.83 (-1.88), GUD.TO: 6.52 (+0.48)
Gilead: Rising Net Income, Zero Debt And Strong R&D Pipeline
Todd Johnson - at Seeking Alpha - Wed Nov 19, 6:45AM CST
GILD: 101.81 (-1.90), BMY: 58.65 (-0.05)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 13.83 (+1.07), GILD: 101.81 (-1.90), FB: 73.81 (-0.53), DNDN: 0.13 (-0.02), MSFT: 48.15 (-0.59), INTC: 34.46 (-0.25), GRPN: 7.33 (-0.04), AAPL: 114.21 (-1.26), CSCO: 26.41 (-0.18)
Final Glance: Biotechnology companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 101.81 (-1.90), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)
Stock Market Today: Oil Slump Fuels S&P 500 to Fresh Record High
at The Street - Tue Nov 18, 3:09PM CST
Three cheers for the S&P 500 which closed the session at an all-time high for a fifth-consecutive session.
SPLS: 13.83 (+1.07), ACT: 268.15 (-1.45), HD: 97.18 (+1.20), MDT: 71.88 (-0.59), XOM: 94.78 (-0.09), AGN: 213.41 (+0.04), URBN: 28.78 (-0.01), TJX: 62.24 (+0.60), GILD: 101.81 (-1.90), TOT: 58.24 (-0.16), TGT: 72.15 (+4.64), LOW: 62.14 (+3.61), CVX: 115.75 (+0.28)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.36 (-0.47), GILD: 101.81 (-1.90), MRK: 59.42 (-0.47), AMGN: 162.14 (-0.10), ABBV: 65.74 (-0.31), BMY: 58.65 (-0.05), CELG: 106.85 (+0.07)
Stock Movers: Why 4 Big Drug Stocks Are Rising Today
at Investor's Business Daily - Tue Nov 18, 1:38PM CST
Drugmakers clustered near the top of IBD's Stocks On The Move list Tuesday afternoon. Actavis (ACT), an Ireland-based maker of generic and branded drugs, shot up more than 7% in huge volume in Tuesday afternoon trading on the stock market today. That...
AGN: 213.47 (+0.10), VRX: 141.98 (+0.04), ACT: 268.15 (-1.45), TARO: 146.32 (-2.34), GILD: 101.83 (-1.88)
Stock Market Today: S&P 500 Rallies as Oil Falls Below $75 a Barrel
at The Street - Tue Nov 18, 1:23PM CST
The S&P 500 smashes its last intraday record high, moving higher after oil falls below $75 a barrel.
URBN: 28.78 (-0.01), AGN: 213.47 (+0.10), HD: 97.18 (+1.20), ACT: 268.15 (-1.45), TERP: 32.00 (-0.75), MDT: 71.88 (-0.59), GILD: 101.83 (-1.88), SUNE: 21.55 (+0.07), HIMX: 6.59 (+0.15), AAPL: 114.21 (-1.26), NOK: 7.74 (-0.19)
Midday Glance: Biotechnology companies
AP - Tue Nov 18, 12:24PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 101.83 (-1.88), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)
Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni
at The Street - Tue Nov 18, 9:48AM CST
Shares of Gilead Sciences (GILD) were up in morning trading Tuesday after the European Commission granted marketing authorization for its hepatitis C treatment Harvoni.
GILD: 101.83 (-1.88)
Early Glance: Biotechnology companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 101.83 (-1.88), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)
Harvoni cleared in Europe
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 9:15AM CST
GILD: 101.83 (-1.88)
European Commission Grants Marketing Authorization for Gilead's Harvoni(R) (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
Business Wire - Tue Nov 18, 9:07AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi(R) in January 2014.
GILD: 101.83 (-1.88)
Next Resistance Level for Gilead Sciences (GILD) is $102.81
Comtex SmarTrend(R) - Tue Nov 18, 8:58AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $100.95 and have already reached the first level of resistance at $101.60. Should the shares continue to rise, the resistance pivots of $102.81 and $104.67 will be of interest.
GILD: 101.83 (-1.88)
Buy Gilead Sciences Now At A Historic Low Valuation
Ken McGaha - at Seeking Alpha - Tue Nov 18, 7:52AM CST
GILD: 101.83 (-1.88)
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
PR Newswire - Tue Nov 18, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), and Alibaba (NYSE:BABA).
KMI: 40.79 (+0.38), GILD: 101.83 (-1.88), HAL: 47.94 (-0.60), AAPL: 114.21 (-1.26), BABA: 108.09 (-2.72), BHI: 62.85 (-0.70)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 101.83 (-1.88), ABBV: 65.75 (-0.30)
GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/
GILD Gilead Sciences Recent Headline News
Update: Gilead's Harvoni Receives Marketing Authorization In Europe
IAEResearch - at Seeking Alpha - 19 mins ago
GILD: 101.83 (-1.88)
Stock Market News for November 19, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 27 mins ago
Rally in healthcare stocks and easing global growth worries boosted benchmarks to finish in the green on Tuesday
URBN: 28.78 (-0.01), AGN: 213.41 (+0.04), HD: 97.18 (+1.20), ACT: 268.15 (-1.45), GILD: 101.83 (-1.88), PFE: 30.35 (-0.24), COV: 97.88 (-0.21), ALXN: 192.83 (+0.46)
Knight Sells Priority Review Voucher to Gilead
Marketwire Canada - Wed Nov 19, 7:00AM CST
Knight Therapeutics Inc., (TSX:GUD) through one of its wholly owned subsidiaries ("Knight"
, today announced the sale of its Neglected Tropical Disease Priority Review Voucher ("PRV" . The PRV was granted to Knight in March of this year with the approval of Impavido(R) (miltefosine) for treatment of patients with visceral, mucosal and cutaneous leishmaniasis. Upon closing of the transaction, Knight will receive US$125 million in cash from Gilead Sciences, Inc. in exchange for the PRV. Knight was advised in the transaction by global investment banking firm, Jefferies LLC. GILD: 101.83 (-1.88), GUD.TO: 6.52 (+0.48)
Gilead: Rising Net Income, Zero Debt And Strong R&D Pipeline
Todd Johnson - at Seeking Alpha - Wed Nov 19, 6:45AM CST
GILD: 101.81 (-1.90), BMY: 58.65 (-0.05)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 13.83 (+1.07), GILD: 101.81 (-1.90), FB: 73.81 (-0.53), DNDN: 0.13 (-0.02), MSFT: 48.15 (-0.59), INTC: 34.46 (-0.25), GRPN: 7.33 (-0.04), AAPL: 114.21 (-1.26), CSCO: 26.41 (-0.18)
Final Glance: Biotechnology companies
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
GILD: 101.81 (-1.90), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)
Stock Market Today: Oil Slump Fuels S&P 500 to Fresh Record High
at The Street - Tue Nov 18, 3:09PM CST
Three cheers for the S&P 500 which closed the session at an all-time high for a fifth-consecutive session.
SPLS: 13.83 (+1.07), ACT: 268.15 (-1.45), HD: 97.18 (+1.20), MDT: 71.88 (-0.59), XOM: 94.78 (-0.09), AGN: 213.41 (+0.04), URBN: 28.78 (-0.01), TJX: 62.24 (+0.60), GILD: 101.81 (-1.90), TOT: 58.24 (-0.16), TGT: 72.15 (+4.64), LOW: 62.14 (+3.61), CVX: 115.75 (+0.28)
Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST
JNJ: 108.36 (-0.47), GILD: 101.81 (-1.90), MRK: 59.42 (-0.47), AMGN: 162.14 (-0.10), ABBV: 65.74 (-0.31), BMY: 58.65 (-0.05), CELG: 106.85 (+0.07)
Stock Movers: Why 4 Big Drug Stocks Are Rising Today
at Investor's Business Daily - Tue Nov 18, 1:38PM CST
Drugmakers clustered near the top of IBD's Stocks On The Move list Tuesday afternoon. Actavis (ACT), an Ireland-based maker of generic and branded drugs, shot up more than 7% in huge volume in Tuesday afternoon trading on the stock market today. That...
AGN: 213.47 (+0.10), VRX: 141.98 (+0.04), ACT: 268.15 (-1.45), TARO: 146.32 (-2.34), GILD: 101.83 (-1.88)
Stock Market Today: S&P 500 Rallies as Oil Falls Below $75 a Barrel
at The Street - Tue Nov 18, 1:23PM CST
The S&P 500 smashes its last intraday record high, moving higher after oil falls below $75 a barrel.
URBN: 28.78 (-0.01), AGN: 213.47 (+0.10), HD: 97.18 (+1.20), ACT: 268.15 (-1.45), TERP: 32.00 (-0.75), MDT: 71.88 (-0.59), GILD: 101.83 (-1.88), SUNE: 21.55 (+0.07), HIMX: 6.59 (+0.15), AAPL: 114.21 (-1.26), NOK: 7.74 (-0.19)
Midday Glance: Biotechnology companies
AP - Tue Nov 18, 12:24PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 101.83 (-1.88), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)
Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni
at The Street - Tue Nov 18, 9:48AM CST
Shares of Gilead Sciences (GILD) were up in morning trading Tuesday after the European Commission granted marketing authorization for its hepatitis C treatment Harvoni.
GILD: 101.83 (-1.88)
Early Glance: Biotechnology companies
AP - Tue Nov 18, 9:23AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 101.83 (-1.88), AMGN: 162.14 (-0.10), CELG: 106.85 (+0.07)
Harvoni cleared in Europe
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 9:15AM CST
GILD: 101.83 (-1.88)
European Commission Grants Marketing Authorization for Gilead's Harvoni(R) (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
Business Wire - Tue Nov 18, 9:07AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi(R) in January 2014.
GILD: 101.83 (-1.88)
Next Resistance Level for Gilead Sciences (GILD) is $102.81
Comtex SmarTrend(R) - Tue Nov 18, 8:58AM CST
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $100.95 and have already reached the first level of resistance at $101.60. Should the shares continue to rise, the resistance pivots of $102.81 and $104.67 will be of interest.
GILD: 101.83 (-1.88)
Buy Gilead Sciences Now At A Historic Low Valuation
Ken McGaha - at Seeking Alpha - Tue Nov 18, 7:52AM CST
GILD: 101.83 (-1.88)
Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
PR Newswire - Tue Nov 18, 7:45AM CST
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), and Alibaba (NYSE:BABA).
KMI: 40.79 (+0.38), GILD: 101.83 (-1.88), HAL: 47.94 (-0.60), AAPL: 114.21 (-1.26), BABA: 108.09 (-2.72), BHI: 62.85 (-0.70)
Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - Tue Nov 18, 7:22AM CST
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 101.83 (-1.88), ABBV: 65.75 (-0.30)
(0)
(0)